-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Protalix BioTherapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2022 to Q3 2025.
- Protalix BioTherapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was -$116K, a 119% decline year-over-year.
- Protalix BioTherapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $1.09M, a 5956% increase year-over-year.
- Protalix BioTherapeutics, Inc. annual Income Tax Expense (Benefit) for 2024 was $1.22M, a 381% increase from 2023.
- Protalix BioTherapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was $254K, a 52.1% decline from 2022.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)